Generic Cytoxan Availability
Last updated on Jun 11, 2025.
Cytoxan is a brand name of cyclophosphamide, approved by the FDA in the following formulation(s):
CYTOXAN (cyclophosphamide - injectable;injection)
-
Manufacturer: BAXTER HLTHCARE
Approved Prior to Jan 1, 1982
Strength(s): 100MG/VIAL (discontinued) [RLD], 200MG/VIAL (discontinued) [RLD]
CYTOXAN (cyclophosphamide - tablet;oral)
-
Manufacturer: BAXTER HLTHCARE
Approved Prior to Jan 1, 1982
Strength(s): 25MG [RLD], 50MG [RLD]
Is there a generic version of Cytoxan available?
An Authorized Generic version of Cytoxan has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance and has exactly the same inactive ingredients.
List of authorized generic versions:
- Cyclophosphamide ORAL TABLET 25 mg
Baxter Healthcare Company
NDC Code: 100190982
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cytoxan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
More about Cytoxan (cyclophosphamide)
- Check interactions
- Compare alternatives
- Reviews (7)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: alkylating agents
- Breastfeeding
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Related/similar drugs
Carvykti
Carvykti (ciltacabtagene autoleucel) is a treatment for relapsed or refractory multiple myeloma ...
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Imbruvica
Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Talvey
Talvey is used to treat relapsed or refractory multiple myeloma. Includes Talvey side effects ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.